Harry R. Büller

57.1k total citations · 23 hit papers
450 papers, 35.7k citations indexed

About

Harry R. Büller is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Harry R. Büller has authored 450 papers receiving a total of 35.7k indexed citations (citations by other indexed papers that have themselves been cited), including 347 papers in Internal Medicine, 226 papers in Cardiology and Cardiovascular Medicine and 122 papers in Hematology. Recurrent topics in Harry R. Büller's work include Venous Thromboembolism Diagnosis and Management (347 papers), Atrial Fibrillation Management and Outcomes (155 papers) and Blood Coagulation and Thrombosis Mechanisms (111 papers). Harry R. Büller is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (347 papers), Atrial Fibrillation Management and Outcomes (155 papers) and Blood Coagulation and Thrombosis Mechanisms (111 papers). Harry R. Büller collaborates with scholars based in Netherlands, United States and Italy. Harry R. Büller's co-authors include Martin H. Prins, Marcello Di Nisio, Jan W. ten Cate, Nick van Es, Saskia Middeldorp, Marcel Levi, Jeffrey I. Weitz, Alexander Gallus, Tom van der Poll and Gary E. Raskob and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Harry R. Büller

442 papers receiving 34.3k citations

Hit Papers

Oral Apixaban for the Treatme... 1989 2026 2001 2013 2013 2017 2012 2007 1996 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Apixaban for the Treatment of Acute Venous Thromboembolism
    2013 1.7k citations Harry R. Büller, Gary E. Raskob et al. profile →
  2. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
    2017 1.1k citations Gary E. Raskob, Nick van Es et al. profile →
  3. Apixaban for Extended Treatment of Venous Thromboembolism
    2012 918 citations Harry R. Büller, Alexander T. Cohen et al. profile →
  4. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    2007 812 citations Martin H. Prins, Harry R. Büller et al. profile →
  5. Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
    1996 810 citations Paolo Prandoni, Franco Piovella et al. profile →
  6. Thrombosis
    2014 744 citations Gary E. Raskob, Pantep Angchaisuksiri et al. profile →
  7. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial
    2007 732 citations Harry R. Büller et al. Journal of Thrombosis and Haemostasis profile →
  8. Bidirectional Relation Between Inflammation and Coagulation
    2004 687 citations Harry R. Büller et al. profile →
  9. Detection of Deep-Vein Thrombosis by Real-Time B-Mode Ultrasonography
    1989 661 citations Paolo Prandoni, Jan W. ten Cate et al. profile →
  10. Deep vein thrombosis and pulmonary embolism
    2016 606 citations Marcello Di Nisio, Nick van Es et al. profile →
  11. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis
    1997 595 citations Harry R. Büller, Menno V. Huisman et al. profile →
  12. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
    2014 581 citations Nick van Es, Michiel Coppens et al. Blood profile →
  13. Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
    2000 550 citations Barbara A. Hutten, Martin H. Prins et al. Journal of Clinical Oncology profile →
  14. Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal Subjects
    1990 514 citations Harry R. Büller, Hugo Ten Cate et al. profile →
  15. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
    1992 484 citations Paolo Prandoni, Harry R. Büller et al. profile →
  16. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
    1992 480 citations Michael T. Nurmohamed, Harry R. Büller et al. profile →
  17. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
    2014 455 citations Harry R. Büller, Gary E. Raskob et al. profile →
  18. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
    2013 436 citations Harry R. Büller et al. profile →
  19. Venous thromboembolism in cancer patients: a population-based cohort study
    2020 399 citations Frits I. Mulder, Erzsébet Horváth–Puhó et al. Blood profile →
  20. Thrombosis: a major contributor to the global disease burden
    2014 344 citations Gary E. Raskob, Pantep Angchaisuksiri et al. Journal of Thrombosis and Haemostasis profile →
  21. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function
    2017 252 citations Walter Ageno, Marjolein Brekelmans et al. profile →
  22. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
    2018 230 citations Nick van Es, Marcello Di Nisio et al. The Lancet Haematology profile →
  23. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis
    2019 204 citations Frits I. Mulder, Pieter W. Kamphuisen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry R. Büller Netherlands 92 24.6k 18.6k 8.6k 8.2k 4.2k 450 35.7k
Martin H. Prins Netherlands 90 19.9k 0.8× 17.7k 0.9× 8.9k 1.0× 6.8k 0.8× 4.3k 1.0× 384 34.7k
Mark Crowther Canada 93 21.4k 0.9× 19.7k 1.1× 10.3k 1.2× 9.2k 1.1× 3.0k 0.7× 584 40.0k
John A. Heit United States 68 23.7k 1.0× 15.2k 0.8× 9.3k 1.1× 6.5k 0.8× 4.3k 1.0× 220 30.9k
Sam Schulman Canada 69 21.5k 0.9× 21.5k 1.2× 7.1k 0.8× 7.7k 0.9× 2.4k 0.6× 501 34.5k
Jeffrey I. Weitz Canada 98 21.1k 0.9× 23.9k 1.3× 9.0k 1.0× 9.2k 1.1× 2.2k 0.5× 528 41.9k
Jack Hirsh Canada 96 22.3k 0.9× 22.7k 1.2× 13.3k 1.6× 8.2k 1.0× 2.1k 0.5× 350 38.4k
Clive Kearon Canada 66 26.6k 1.1× 20.1k 1.1× 9.7k 1.1× 5.9k 0.7× 5.2k 1.2× 230 33.5k
Menno V. Huisman Netherlands 76 20.0k 0.8× 15.5k 0.8× 5.8k 0.7× 3.2k 0.4× 3.5k 0.8× 469 29.6k
Samuel Z. Goldhaber United States 100 35.0k 1.4× 27.6k 1.5× 10.6k 1.2× 5.4k 0.7× 6.3k 1.5× 614 47.4k
Susan R. Kahn Canada 70 20.3k 0.8× 11.5k 0.6× 10.0k 1.2× 4.2k 0.5× 5.4k 1.3× 330 25.8k

Countries citing papers authored by Harry R. Büller

Since Specialization
Citations

This map shows the geographic impact of Harry R. Büller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry R. Büller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry R. Büller more than expected).

Fields of papers citing papers by Harry R. Büller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry R. Büller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry R. Büller. The network helps show where Harry R. Büller may publish in the future.

Co-authorship network of co-authors of Harry R. Büller

This figure shows the co-authorship network connecting the top 25 collaborators of Harry R. Büller. A scholar is included among the top collaborators of Harry R. Büller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry R. Büller. Harry R. Büller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mulder, Frits I., Erzsébet Horváth–Puhó, Nick van Es, et al.. (2020). Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 137(14). 1959–1969. 399 indexed citations breakdown →
2.
Tritschler, Tobias, Noémie Kraaijpoel, Philippe Girard, et al.. (2020). Definition of pulmonary embolism‐related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18(6). 1495–1500. 37 indexed citations
3.
Leader, Avi, Eva N. Hamulyák, Ludo F.M. Beenen, et al.. (2020). Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Advances. 4(24). 6291–6297. 33 indexed citations
4.
Mulder, Frits I., Marcello Di Nisio, Cihan Ay, et al.. (2019). Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal. 55(2). 1901697–1901697. 31 indexed citations
5.
Wang, Kang-Ling, Nick van Es, Chris Cameron, et al.. (2018). Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart. 105(7). 545–552. 24 indexed citations
6.
Robert‐Ebadi, Helia, Marcel M.C. Hovens, Franck Verschuren, et al.. (2017). Assessing clinical probability of pulmonary embolism: prospective validation of the simplified Geneva score. Journal of Thrombosis and Haemostasis. 15(9). 1764–1769. 18 indexed citations
7.
Hutten, Barbara A., et al.. (2016). PO-28 - Protein C levels are associated with mortality in patients with advanced cancer. Thrombosis Research. 140. S186–S187. 3 indexed citations
8.
Brekelmans, Marjolein, Walter Ageno, Ludo F.M. Beenen, et al.. (2016). Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3(9). e437–e445. 25 indexed citations
9.
Es, Nick van, Michiel Coppens, Sam Schulman, Saskia Middeldorp, & Harry R. Büller. (2014). Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 124(12). 1968–1975. 581 indexed citations breakdown →
10.
Raskob, Gary E., Harry R. Büller, Pantep Angchaisuksiri, et al.. (2013). Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. Blood. 122(21). 211–211. 18 indexed citations
11.
Büller, Harry R., et al.. (2012). Oral Rivaroxaban for Pulmonary Embolism REPLY. Data Archiving and Networked Services (DANS).
12.
Lane, Deirdre A., Pieter W. Kamphuisen, Pascal Minini, Harry R. Büller, & Gregory Y.H. Lip. (2010). Safety and efficacy of anticoagulation for secondary stroke prevention in atrial fibrillation patients: The AMADEUS trial. University of Groningen research database (University of Groningen / Centre for Information Technology). 2 indexed citations
13.
Kaandorp, S. P., Mariëtte Goddijn, Joris van der Post, et al.. (2010). Aspirin Plus Heparin or Aspirin Alone in Women With Recurrent Miscarriage. Obstetrical & Gynecological Survey. 65(10). 621–622. 253 indexed citations
14.
Douma, Renée A., Grégoire Le Gal, Maaike Söhne, et al.. (2009). Age-adjusted d-dimer cut-off levels increase the clinical utility of ruling out pulmonary embolism in elderly patients. Journal of Thrombosis and Haemostasis. 7. 3 indexed citations
15.
Söhne, Maaike, Marieke J.H.A. Kruip, Mathilde Nijkeuter, et al.. (2006). Accuracy of clinical decision rule, D‐dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. Journal of Thrombosis and Haemostasis. 4(5). 1042–1046. 52 indexed citations
16.
Klerk, Clara, Susanne M. Smorenburg, Hans-Martin Otten, et al.. (2005). The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy. Journal of Clinical Oncology. 23(10). 2130–2135. 481 indexed citations
17.
Moons, Karel G.M., et al.. (1999). Redundancy of Single Diagnostic Test Evaluation. Epidemiology. 10(3). 276–281. 67 indexed citations
18.
Hoek, J A, Michael T. Nurmohamed, Renaud Marti, et al.. (1992). Prevention of Deep Vein Thrombosis following Total Hip Replacement by Low Molecular Weight Heparinoid. Thrombosis and Haemostasis. 67(1). 28–32. 93 indexed citations
19.
Cate, Hugo Ten, Ch. P. Henny, Jan W. ten Cate, Harry R. Büller, & N.F. Dabhoiwala. (1987). Randomized Double-Blind, Placebo Controlled Safety Study of a Low Molecular Weight Heparinoid in Patients Undergoing Transurethral Resection of the Prostate. Thrombosis and Haemostasis. 57(1). 92–96. 21 indexed citations
20.
Henny, Ch. P., Hugo Ten Cate, J W ten Cate, et al.. (1986). Thrombosis Prophylaxis in an AT III Deficient Pregnant Woman: Application of a Low Molecular Weight Heparinoid. Thrombosis and Haemostasis. 55(2). 301–301. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin H. Prins Breakdown of academic impact, for papers by Mark Crowther Breakdown of academic impact, for papers by John A. Heit Breakdown of academic impact, for papers by Sam Schulman Breakdown of academic impact, for papers by Jeffrey I. Weitz Breakdown of academic impact, for papers by Jack Hirsh Breakdown of academic impact, for papers by Clive Kearon Breakdown of academic impact, for papers by Menno V. Huisman Breakdown of academic impact, for papers by Samuel Z. Goldhaber Breakdown of academic impact, for papers by Susan R. Kahn
Rankless by CCL
2026